Form 4: Rhythm Pharmaceuticals Executive Sells Shares
Insider Transaction (Form 4)
Yann Mazabraud, EVP, Head of International of Rhythm Pharmaceuticals, Inc., sold 57,000 shares of common stock on August 12, 2026.
Summary
- Option exercise/conversion: acquired 46,625 Common Stock at $6.80 ($317,050) on August 12, 2026; holds 112,655 after (Direct).
- Open-market sale: disposed of 2,300 Common Stock at $111.80 ($257,138) on August 12, 2026; holds 110,355 after (Direct).
- Open-market sale: disposed of 1,000 Common Stock at $112.86 ($112,856) on August 12, 2026; holds 109,355 after (Direct).
- Open-market sale: disposed of 3,605 Common Stock at $114.70 ($413,477) on August 12, 2026; holds 105,750 after (Direct).
- Open-market sale: disposed of 14,568 Common Stock at $115.43 ($1,681,541) on August 12, 2026; holds 91,182 after (Direct).
- Open-market sale: disposed of 18,208 Common Stock at $116.49 ($2,121,125) on August 12, 2026; holds 72,974 after (Direct).
- Open-market sale: disposed of 17,319 Common Stock at $117.47 ($2,034,439) on August 12, 2026; holds 55,655 after (Direct).
- Option exercise/conversion: disposed of 46,625 Stock Options (Right to Buy) on August 12, 2026; holds 35,875 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $6,620,575 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Yann Mazabraud — Officer (EVP, Head of International)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 46,625 | $7 | $317.1K | 112,655 |
| 2026-08-12 | Open-market sale | Common Stock | 2,300 | $112 | $257.1K | 110,355 |
| 2026-08-12 | Open-market sale | Common Stock | 1,000 | $113 | $112.9K | 109,355 |
| 2026-08-12 | Open-market sale | Common Stock | 3,605 | $115 | $413.5K | 105,750 |
| 2026-08-12 | Open-market sale | Common Stock | 14,568 | $115 | $1.7M | 91,182 |
| 2026-08-12 | Open-market sale | Common Stock | 18,208 | $116 | $2.1M | 72,974 |
| 2026-08-12 | Open-market sale | Common Stock | 17,319 | $117 | $2.0M | 55,655 |
| 2026-08-12 | Option exercise/conversion | Stock Options (Right to Buy) | 46,625 | — | — | 35,875 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (46,625 shares) |
| 2026-08-12 | Open-market sale (2,300 shares) |
| 2026-08-12 | Open-market sale (1,000 shares) |
| 2026-08-12 | Open-market sale (3,605 shares) |
| 2026-08-12 | Open-market sale (14,568 shares) |
| 2026-08-12 | Open-market sale (18,208 shares) |
| 2026-08-12 | Open-market sale (17,319 shares) |
| 2026-08-12 | Option exercise/conversion (46,625 shares) |
Keywords
insider transaction, Form 4, RYTM, RHYTHM PHARMACEUTICALS, INC., bearish, Yann Mazabraud
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.